Skip to content
Menu

Taysha Gene Therapies, Inc. TSHA

Full chart Compare
Set alert

Price alert · TSHA

All alert types
3.77 USD -0.22 (-5.51%)

Regular-session close

3.77 0.00 0.00%

After hours · Nov 19, 4:01 PM ET

3.75 Day range 4.13
3.46 52-week range 7.30
YTD
-31.45%
1 year
-5.99%

5D -0.42 (-9.95%)

3.8044.20FriMonTueWedThu3.80
Market cap
1.23B
Revenue (ttm)
5.49M
EPS (ttm)
-0.42
Shares out
326.05M
Forward P/E
-9.73
YTD return
-31.45%
1-year return
-5.99%
50-day average
4.40
200-day average
5.29
Enterprise value
932.68M
Volume
2.17M
Avg volume
3.61M
Open
4.01
Previous close
3.99
Day's range
3.75 – 4.13
52-week range
3.46 – 7.30
Beta
1.31
Analysts
Strong Buy
Price target
13.00 (+244.8%)
Earnings date
Mar 18, 2027

Key statistics

Price / sales
224.10
Price / book
3.44
Free cash flow
-90.18M
Total cash
422.83M
Total debt
54.59M
Return on equity
-54.18%
Short % of float
16.67%

Fundamental scorecard

4 of 25 checks passed on TSHA’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
TSHA Revenue — quarterly 0
TSHA Net income — quarterly -39.13M
TSHA EPS — quarterly -0.10

Earnings

TSHA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 18, 2027Dec 30, 2026-0.11———
Nov 12, 2026Sep 30, 2026-0.12857-0.10+0.03+22.22%
Aug 11, 2026Jun 30, 2026-0.11327-0.13-0.02-14.77%
May 6, 2026Mar 31, 2026-0.10-0.12-0.02-20.00%
Mar 19, 2026Dec 31, 2025-0.11-0.08+0.03+27.27%
Nov 4, 2025Sep 30, 2025-0.09-0.090.000.00%

Upgrades / downgrades

TSHA analyst upgrades and downgrades
DateFirmActionFromTo
Sep 17, 2026Wolfe Researchinit—Outperform
Jul 21, 2026Goldman SachsmainBuyBuy
Jul 2, 2026CitizensreitMarket OutperformMarket Outperform
Jun 30, 2026NeedhammainBuyBuy
Jun 30, 2026BairdmainOutperformOutperform
Jun 23, 2026BMO CapitalmainOutperformOutperform

About Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on TSHA — it syncs with the Stock Master app.

Insider holders

TSHA insider holders
InsiderRelationLatest transactionDateShares held
ALAM KAMRANChief Financial OfficerSaleFeb 3, 20261,442,130
DONENBERG PHILLIP BRIANDirectorStock Award(Grant)May 31, 2026241,289
LONG ALISON SDirectorStock Award(Grant)May 31, 2026127,178
MANNING PAUL B.Beneficial Owner of more than 10% of a Class of SecurityPurchaseMay 29, 20250
NAGENDRAN SUKUMAROfficer and DirectorSaleJul 9, 2026936,410
NOLAN SEAN PATRICKChief Executive OfficerSaleJan 25, 20264,443,800

Institution ownership

TSHA institution ownership
Holder% heldSharesValueReported
RA Capital Management, L.P.9.33%30,435,190114.74MSep 29, 2026
Goldman Sachs Group Inc7.70%25,115,51994.69MSep 29, 2026
Avoro Capital Advisors LLC7.33%23,888,88890.06MSep 29, 2026
Blackrock Inc.6.95%22,651,99985.40MSep 29, 2026
Vestal Point Capital, LP5.53%18,045,00068.03MSep 29, 2026
Morgan Stanley4.82%15,722,73559.27MSep 29, 2026

Fund ownership

TSHA fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.80%9,138,04334.45MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.11%6,895,32526.00MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.58%5,138,80319.37MSep 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund1.28%4,170,94815.72MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund0.93%3,044,55411.48MJun 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund0.81%2,626,9379.90MAug 30, 2026